NASDAQ:JAGX Jaguar Health (JAGX) Stock Price, News & Analysis → Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (From Weiss Ratings) (Ad) Free JAGX Stock Alerts $4.22 -0.07 (-1.63%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share Today's Range$4.06▼$4.3950-Day Range$4.03▼$19.0852-Week Range$3.07▼$43.20Volume826,900 shsAverage Volume912,832 shsMarket Capitalization$20.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Jaguar Health alerts: Email Address Jaguar Health MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.42) to ($4.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.58 out of 5 starsMedical Sector859th out of 924 stocksPharmaceutical Preparations Industry407th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Jaguar Health.Read more about Jaguar Health's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.32% of the outstanding shares of Jaguar Health have been sold short.Short Interest Ratio / Days to CoverJaguar Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Health has recently decreased by 98.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJaguar Health does not currently pay a dividend.Dividend GrowthJaguar Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JAGX. Previous Next 2.7 News and Social Media Coverage News SentimentJaguar Health has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Jaguar Health this week, compared to 2 articles on an average week.Search Interest58 people have searched for JAGX on MarketBeat in the last 30 days. This is an increase of 132% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jaguar Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Jaguar Health is held by insiders.Percentage Held by InstitutionsOnly 12.04% of the stock of Jaguar Health is held by institutions.Read more about Jaguar Health's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jaguar Health are expected to grow in the coming year, from ($5.42) to ($4.22) per share.Price to Book Value per Share RatioJaguar Health has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jaguar Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyI’m afraid WWIII is a very real possibility As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look. About Jaguar Health Stock (NASDAQ:JAGX)Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Read More JAGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAGX Stock News HeadlinesJune 2 at 6:54 AM | americanbankingnews.comJaguar Health (NASDAQ:JAGX) Raised to Hold at StockNews.comMay 29, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for SchizophreniaMay 29, 2024 | finance.yahoo.comJaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for SchizophreniaMay 28, 2024 | finanznachrichten.deJaguar Health, Inc.: Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional DiarrheaMay 28, 2024 | finance.yahoo.comInvestigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional DiarrheaMay 26, 2024 | americanbankingnews.comJaguar Health (NASDAQ:JAGX) Sees Strong Trading VolumeMay 24, 2024 | americanbankingnews.comJaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.comMay 23, 2024 | finance.yahoo.comJaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis ProductMay 15, 2024 | finance.yahoo.comJaguar Health Inc (JAGX) Q1 2024 Earnings Call Transcript Highlights: Strategic Expansions and ...May 14, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comJAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | msn.comJaguar Health Q1 2024 Earnings PreviewMay 10, 2024 | benzinga.comLatest News for Jaguar Health Stock (NASDAQ:JAGX)May 10, 2024 | benzinga.comPeering Into Jaguar Health's Recent Short InterestMay 7, 2024 | investorplace.comWant $10,000? Invest $1,000 in These 3 Penny Stocks NowMay 6, 2024 | finance.yahoo.comCrofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in DogsApril 17, 2024 | msn.comWhy Jaguar Health Stock Is Up TodayApril 17, 2024 | markets.businessinsider.comGold Moves Higher; Morgan Stanley Earnings Top ViewsApril 16, 2024 | investorplace.comWhy Is Jaguar Health (JAGX) Stock Up 44% Today?April 10, 2024 | benzinga.comS&P 500 Down 1%; Delta Air Lines Posts Upbeat EarningsApril 10, 2024 | msn.comJaguar Health shareholders approve reverse stock splitApril 10, 2024 | investorplace.comWhat Is Going on With Jaguar Health (JAGX) Stock Today?April 10, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of StockholdersApril 9, 2024 | msn.comWhy Jaguar Health Stock Is Soaring After-HoursApril 3, 2024 | finance.yahoo.comJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)See More Headlines Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/02/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JAGX CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,300,000.00 Net Margins-377.95% Pretax Margin-383.35% Return on Equity-642.15% Return on Assets-75.53% Debt Debt-to-Equity Ratio1.84 Current Ratio1.89 Quick Ratio1.39 Sales & Book Value Annual Sales$9.76 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book1.75Miscellaneous Outstanding Shares4,900,000Free Float4,905,000Market Cap$20.68 million OptionableNo Data Beta0.89 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Lisa A. Conte (Age 65)Founder, CEO, President & Director Comp: $610.66kDr. Pravin R. Chaturvedi Ph.D. (Age 61)Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $517.91kDr. Steven R. King Ph.D. (Age 66)Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary Comp: $406.4kMs. Carol R. Lizak M.B.A. (Age 60)Chief Financial Officer Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special EventsDr. Karen J. Brunke Ph.D. (Age 71)Executive VP of Corporate & Business Development Mr. Ian H. Wendt M.B.A. (Age 56)Chief Commercial Officer Comp: $441.31kDr. Massimo Radaelli M.B.A. (Age 66)Ph.D., President of Jaguar International Ms. Catherine Miller CollisSenior Vice President of Growth StrategyMore ExecutivesKey CompetitorsCue BiopharmaNASDAQ:CUESpero TherapeuticsNASDAQ:SPROHookipa PharmaNASDAQ:HOOKEupraxia PharmaceuticalsNASDAQ:EPRXPyroGenesis CanadaNASDAQ:PYRGFView All Competitors JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed in 2024? Jaguar Health's stock was trading at $9.0840 at the beginning of the year. Since then, JAGX stock has decreased by 53.5% and is now trading at $4.22. View the best growth stocks for 2024 here. Are investors shorting Jaguar Health? Jaguar Health saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 211,800 shares, a drop of 98.5% from the April 30th total of 14,330,000 shares. Based on an average trading volume of 1,220,000 shares, the days-to-cover ratio is presently 0.2 days. View Jaguar Health's Short Interest. When is Jaguar Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our JAGX earnings forecast. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) released its earnings results on Tuesday, May, 14th. The biotechnology company reported ($3.60) EPS for the quarter. The biotechnology company earned $2.35 million during the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 642.15% and a negative net margin of 377.95%. When did Jaguar Health's stock split? Shares of Jaguar Health reverse split on the morning of Thursday, May 23rd 2024. The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT). When did Jaguar Health IPO? Jaguar Health (JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JAGX) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group"Trump Loophole" Beats InflationColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.